CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

DEAR PEOPLE’S PHARMACY: I’ve been on Ozempic for several months now. My blood sugar in the morning is around 103, down from ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers' Chief Operating Officer Melissa Baird will transition into an advisory role with the telehealth company in the coming months.

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Zacks Equity Research shares Hims & Hers Health HIMS as the Bull of the Day and AST SpaceMobile ASTS as the Bear of the D ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...

Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S (NYSE: NVO) Wegovy. Hims will ...